Skip Nav Destination
Issues
The Biology Behind
Featured Articles
Clinical Trials
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Francis Giles; Deborah Thomas; Guillermo Garcia-Manero; Stefan Faderl; Jorge Cortes; Srdan Verstovsek; Alessandra Ferrajoli; Sima Jeha; Miloslav Beran; Charles Koller; Michael Andreeff; Ann Cahill; Caroline Clairmont; Mario Sznol; Hagop Kantarjian
Molecular Oncology, Markers, Clinical Correlates
DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies
Takao Takahashi; Narayan Shivapurkar; Jyotsna Reddy; Hisayuki Shigematsu; Kuniharu Miyajima; Makoto Suzuki; Shinichi Toyooka; Sabine Zöchbauer-Müller; Johannes Drach; Gunjan Parikh; Yingye Zheng; Ziding Feng; Steven H. Kroft; Charles Timmons; Robert W. McKenna; Adi F. Gazdar
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination
Lucy J. C. Smyth; Mariëtte I. E. van Poelgeest; Emma J. Davidson; Kitty M. C. Kwappenberg; Debbie Burt; Peter Sehr; Michael Pawlita; Stephen Man; Julian K. Hickling; Alison N. Fiander; Amanda Tristram; Henry C. Kitchener; Rienk Offringa; Peter L. Stern; Sjoerd H. van der Burg
Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer: Results of a Phase I/II Trial
Paul Sabbatini; Carol Aghajanian; Mario Leitao; Ennapadam Venkatraman; Sybil Anderson; Jakob Dupont; Don Dizon; Catherine O’Flaherty; Jeffrey Bloss; Dennis Chi; David Spriggs
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors
Fadlo R. Khuri; Bonnie S. Glisson; Edward S. Kim; Paul Statkevich; Peter F. Thall; Michael L. Meyers; Roy S. Herbst; Reginald F. Munden; Craig Tendler; Yali Zhu; Sandra Bangert; Elizabeth Thompson; Charles Lu; Xue-Mei Wang; Dong M. Shin; Merrill S. Kies; Vali Papadimitrakopoulou; Frank V. Fossella; Paul Kirschmeier; W. Robert Bishop; Waun Ki Hong
A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene
Srinivasan Madhusudan; Ayala Tamir; Nicholas Bates; Elizabeth Flanagan; Martin E. Gore; Desmond P. J. Barton; Peter Harper; Michael Seckl; Hilary Thomas; Nicholas R. Lemoine; Mark Charnock; Nagy A. Habib; Robert Lechler; Joanna Nicholls; Massimo Pignatelli; Trivadi S. Ganesan
Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging
Michael C. Frühwald; Christian H. Rickert; M. Sue O’Dorisio; Mark Madsen; Monika Warmuth-Metz; Geetika Khanna; Werner Paulus; Joachim Kühl; Heribert Jürgens; Peter Schneider; Hermann L. Müller
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Comparative Study between DNA Copy Number Aberrations Determined by Quantitative Microsatellite Analysis and Clinical Outcome in Patients with Stomach Cancer
Seiji Suzuki; Kaku Egami; Koji Sasajima; Mohammad Ghazizadeh; Hajime Shimizu; Hidehiro Watanabe; Hirokazu Hasegawa; Shinya Iida; Takeshi Matsuda; Yuji Okihama; Masaru Hosone; Kazuo Shimizu; Oichi Kawanami; Takashi Tajiri
Reliable and Sensitive Identification of Occult Tumor Cells Using the Improved Rare Event Imaging System
Stine-Kathrein Kraeft; Andras Ladanyi; Kevin Galiger; Anna Herlitz; Andrew C. Sher; Danielle E. Bergsrud; Gaelle Even; Stephanie Brunelle; Lyndsay Harris; Ravi Salgia; Tom Dahl; John Kesterson; Lan Bo Chen
The Prognostic Value of Isolated Tumor Cells in Bone Marrow in Breast Cancer Patients: Evaluation of Morphological Categories and the Number of Clinically Significant Cells
Bjørn Naume; Gro Wiedswang; Elin Borgen; Gunnar Kvalheim; Rolf Kåresen; Hanne Qvist; Jan Janbu; Torstein Harbitz; Jahn M. Nesland
Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival
Meri Varga; Peter Obrist; Stephan Schneeberger; Gilbert Mühlmann; Christina Felgel-Farnholz; Dominic Fong; Mathias Zitt; Thomas Brunhuber; Georg Schäfer; Guenther Gastl; Gilbert Spizzo
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors
Bei Zheng; Georgios V. Georgakis; Yang Li; Alok Bharti; David McConkey; Bharat B. Aggarwal; Anas Younes
Experimental Therapeutics, Preclinical Pharmacology
Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-Biotin
Zhengsheng Yao; Meili Zhang; Kayhan Garmestani; Donald B. Axworthy; Robert W. Mallett; Alan R. Fritzberg; Lou J. Theodore; Paul S. Plascjak; William C. Eckelman; Thomas A. Waldmann; Ira Pastan; Chang H. Paik; Martin W. Brechbiel; Jorge A. Carrasquillo
Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with the in Vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II
Anna Kruczynski; Jean-Marc Barret; Benoît van Hille; Nathalie Chansard; Jackie Astruc; Yoann Menon; Carole Duchier; Laurent Créancier; Bridget T. Hill
Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme
Chris A. Learn; Tristan L. Hartzell; Carol J. Wikstrand; Gary E. Archer; Jeremy N. Rich; Allan H. Friedman; Henry S. Friedman; Darell D. Bigner; John H. Sampson
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.